Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
AstraZeneca PLC
Type
Public limited company
Traded as LSE: AZN
OMX: AZN
NYSE: AZN
Industry Pharmaceutical
Biotechnology
Predecessor Astra AB
Zeneca Group plc
Founded 6 April 1999
Headquarters London, United Kingdom
Area served
Global
Key people
Leif Johansson (Chairman)
Pascal Soriot (CEO)
Products Pharmaceutical products
Revenue US$26.095 billion (2014)
Operating income
US$2.137 billion(2014)
Net income
US$1.235 billion (2014)
Number of employees
50,000 (2014)
Subsidiaries MedImmune
Website www.astrazeneca.com

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales (after Pfizer, Sanofi, Novartis, Merck & Co., Roche and GlaxoSmithKline) and has operations in over 100 countries.

Astra
(Founded 1913)

Tika
(Acq 1939)

Zeneca
(Spun off from Imperial Chemical Industries 1993)

Salick Health Care
(Acq 1996)

Ishihara Sangyo Kaisha
(US fungicide operations, Acq 1997)

KuDOS Pharmaceuticals
(Acq 2005)

Cambridge Antibody Technology
(Acq 2006)

Aptein Inc
(Acq 1998)

Arrow Therapeutics
(Acq 2007)

MedImmune
(Acq 2007)

Definiens
(Acq 2014)

Novexel Corp
(Acq 2010)

Guangdong BeiKang Pharmaceutical Company
(Acq 2011)

Ardea Biosciences
(Acq 2012)

Amylin Pharmaceuticals
(Acq 2012 jointly with Bristol-Myers Squibb )

Spirogen
(Acq 2013)

Pearl Therapeutics
(Acq 2013)

Omthera Pharmaceuticals
(Acq 2013)

Bristol-Myers Squibb
(share of global diabetes alliance, Acq 2013)

Entasis Therapeutics
(Spun off 2015)

– Cardiovascular

– Diabetes

– Infectious diseases

– Neuroscience

– Oncology

– Respiratory and inflammatory diseases

In April 2015 AstraZeneca's drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma in the United States. It awaits FDA approval prior to marketing.

Investment goal date:
Dividends reinvested
AstraZeneca PLC AZN report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-02
--
--
Q3 2017
2017-11-09
--
--
Q2 2017
2017-07-27
0.4400
0.1900
Q1 2017
2017-04-27
0.5000
0.2100
Q4 2016
2017-02-02
0.6100
0.7300
Q3 2016
2016-11-10
0.6600
0.4000
Q2 2016
2016-07-28
0.8300
0.0000
Q1 2016
2016-04-29
0.4800
0.2600
Q4 2015
2016-02-04
0.4700
0.3200
Q3 2015
2015-11-05
0.5200
0.3000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF AMERICA CORP /DE/
45744976
BlackRock Inc.
6910657
BlackRock Investment Management, LLC
6002547
Capital International Investors
18511599
DODGE & COX
56906499
Epoch Investment Partners, Inc.
7668993
FEDERATED INVESTORS INC /PA/
4328514
FMR LLC
3995336
MANAGED ACCOUNT ADVISORS LLC
4415683
PRICE T ROWE ASSOCIATES INC /MD/
12167069
PRIMECAP MANAGEMENT CO/CA/
34310950
PUTNAM INVESTMENTS LLC
4315787
SCHAFER CULLEN CAPITAL MANAGEMENT INC
4202262
WELLINGTON MANAGEMENT CO LLP
63250780
WELLS FARGO & CO/MN
4068018
Major Shareholders
Name Relationship
Total Shares
Holding stocks